Cor Vasa 2004, 45(10):467-471

Hypertension and cardiovascular disease following renal transplantation

Vladimír Teplan*, Jarmila Stříbrná, Vladimír Hanzal, Marcela Bürgelová, Milena Štollová, Jelena Skibová
Klinika nefrologie, Institut klinické a experimentální medicíny, Praha, Česká republika

Aim:
Hypertension after renal transplantation is a known independent non-immune risk factor affecting the mortality and morbidity of renal graft recipients. Our 3-year study was designed to determine the prevalence of hypertension, success of its pharmacological management, and the incidence of cardiovascular disease following renal transplantation.

Method:
A total of 422 renal graft recipients were included into the study. Of this number, 310 individuals completed follow-up with a functioning graft from 3 to 36 months post-transplant. All individuals treated with antihypertensive agents were considered hypertensives while normotension was defined as a blood pressure (BP) lower than 140/90 mm Hg. Assessment included serum creatinine levels and antihypertensive therapy and cardiovascular disease in the patients' medical records.

Results:
A high prevalence of hypertension was found which rose from an initial 94% to 98%. The number of antihypertensive agents used was rising, with the use of triple and multiple combinations increasing from 17 % to 34 % of treated hypertensives. Success rates of drug therapy, i. e., the reaching of goal blood pressure levels, rose significantly (p < 0.01) from an initial 26% to 38% at 36 months. Mean serum creatinine levels increased significantly (p < 0.05) only in a subgroup of renal graft recipients with moderate to severe hypertension, characterized by triple to multiple drug antihypertensive combinations (increase from 150 ± 48 to 159 ± 55 µmol/L). During follow-up, cardiovascular disease-related morbidity was observed in 17 individuals (5.5%), however, 45 (14.6%) patients undergoing transplantation had a history of this disease. Thus, among the 310 renal graft recipients, cardiovascular disease was present in 62, mainly elderly individuals (20%). Mortality from cardiovascular disease was high, it was found in 25 out of the 56 patients who died (45%).

Conclusion:
Hypertension after renal transplantation is the most common non-immune risk factor for graft function and cardiovascular disease. A major role in preventing these complications is played by improved drug treatment of hypertension to achieve goal blood pressure levels.

Keywords: Renal transplantation; Hypertension; Cardiovascular disease

Published: October 1, 2004  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Teplan V, Stříbrná J, Hanzal V, Bürgelová M, Štollová M, Skibová J. Hypertension and cardiovascular disease following renal transplantation. Cor Vasa. 2004;45(10):467-471.
Download citation




Cor et Vasa

You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.